'Science' says Abbott is a Top Employer

AbbottThe journal Science has recognized Abbott (NYSE: ABT) as a Top 20 Employer. The global healthcare company ranked No. 14 overall, receiving high marks for social responsibility, employee loyalty, and having a work culture that aligns with the values of its employees.

This marks the 12th time Abbott has been included in Science magazine's annual ranking, which is voted on by scientists who are asked to select the companies they considered best, average, and worst employers. The complete rankings are available online and in the Oct. 30, 2015, print edition of Science.

"The people who work at Abbott are passionate about advancing science and technology, and we're happy to support them in reaching their professional best," said Robert Miller, Ph.D., co-chair of Abbott's Scientific Governing Board, which oversees the company's 1,700 scientists. "With our global footprint and diverse business profile, scientists can have multiple careers within the same company at Abbott."

As part of its mission to bring new products and technologies to the world, Abbott this year brought renewed focus to the concept of "open innovation" with business partners, universities, and start-ups. This increases opportunities for Abbott's scientists to work on new technologies and inventions.

In Abbott's diagnostics business, an example of open innovation includes a recent partnership with the U.S. Department of Defense to develop a portable blood test to rapidly diagnose concussions and traumatic brain injury. In the company's nutrition business, academic partnerships with the University of Illinois Urbana-Champaign, the University of Singapore and the University of Granada in Spain are helping Abbott scientists explore the cognitive benefits of nutrition.

Scientists at Abbott are given opportunities to advance science, technology, medicine and nutrition to help people live fuller and more complete lives. The company recognizes this commitment through a number of internal recognition efforts, including chairman's awards, president's awards, and patent and inventor awards. The company honors its most distinguished scientists and engineers with induction into the prestigious Volwiler Society, named for the late Ernest H. Volwiler, Ph.D., an internationally recognized scientist and former Abbott president and chairman of the board.

In addition to being honored for workplace leadership by Science, FORTUNE magazine has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983. Working Mother and DiversityInc magazines have also ranked Abbott as a top employer, and the National Association for Female Executives again named Abbott among the Top 50 Companies for Executive Women in 2015.

About the 2015 Science Survey
Science conducted a web-based survey aimed at determining the companies in the biotechnology and pharmaceutical industries with the best reputations as employers. Survey respondents were asked to select the companies they considered best, average, and worst employers. They then rated these companies on 23 different attributes including Image, Financial Prowess, Leadership and Direction, Work Culture/Environment, Location, and Academic and Intellectual Challenge. The report is based on a total sample of 5,701 people. The vast majority of survey participants came from North America (58%), Europe (27%), and Asia/Pacific Rim (11%).

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...